



Drug Utilization Review Board Meeting

<u>Date</u>	<u>Time</u>	<u>Location</u>
April 20, 2022	10:00am – 3:00pm (CST)	MHD Building 615 Howerton Ct, Jefferson City, MO 65101 and WebEx

[* Click HERE for Meeting Documents *](#)

Board Members Present:

Susan Abdel-Rahman, PharmD
Kimberly Eisenstein, MD
Lisa Pierce, MD
Jennifer Passanise, FNP
Stacy Mangum, PharmD
Ginger Nicol, MD, CEDS
Rick Kegler, PharmD
Charlene Hyde, PharmD
Sandra Bollinger, PharmD
Julie Ferguson, DO

Board Members Absent:

MO HealthNet Staff Present:

Joshua Moore, PharmD, Director of Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Angela Wilson, Pharmacy Operations
Manager
Olivia Rush, PharmD, Program Integrity
Pharmacist
Elizabeth Sissom, RN, Clinical Management
Nikki Ashley, Pharmacy Program Specialist
Carmen Burton, Administrative Assistant
Timothy Kling, MD, Acting Medical Director
Elizabeth Short, Program Development
Specialist
Connie Sutter, Fiscal Manager
Kathy Heriford, Benefit Program Senior
Specialist
Lisa Smith, RFP Coordinator
Lori Bushner, BSN, RN, Registered Nurse
Specialist

Contractors in Attendance:

April Ash, PharmD, Conduent
Blake Shrout, PharmD, AAHIVP,
Conduent
Jennifer Colozza, PharmD, Conduent
Ashleigh Holeman, PharmD, Conduent
Megan Fast, PharmD, Conduent
Renee Clark, PharmD, Conduent
Paul Fung, PharmD, MHA Conduent
Chelsea Pendleton, RN, BSN, Wipro
Geri Roling, RN, Wipro
Valerie Schmitz, RN, BSN, Wipro

Others Attending:

Anabelle Keohane
Brenda McLaughlin
Brent Young
Brian Strickland
Brooke Wilkins
Camille Kerr
Carrie Davis
Creed Cultra
Dana Garner
Donald Nopper
GCampbell
Jackie Adamec
James Baumann
Janie Huff
Jeff Knappen
Jenny Carrell
Jessica Petrie
Jim Maxson
John Bullard
Jordan
Karen Powell
Karli Sekab
Kathrine Rivera-Spoljaric

Kerry Young
Kevin Mann
Kevin Wake
Kurt Hendrickson
Lee Stout
Lisa Tracz
Madelin Shurtleff
Maggie Z
Marty Raleigh
Mary Koboldt
Melissa Basil
Michele Shirley
Nishil Patel
Rick Andrews
Ricki Roberson
Rosemary Britts
Sam Marshall
Sandy Kapur
Santreis Booze
Sara Hovland
Serena Barden
Tom Cogan
WellHealth Clinic

<p align="center">Welcome, Introductions and Opening Remarks</p>	<p>Susan Abdel-Rahman, Board Chair, called the meeting to order.</p> <p>Joshua Moore, MHD Director of Pharmacy, introduced himself along with Nikki Ashley, MHD's new Pharmacy Program Specialist, Lisa Smith, who has been promoted to MHD's RFP Coordinator, and Renee Clark, the new Clinical Services Director with Conduent. Joshua facilitated the meeting on behalf of the MO HealthNet Division.</p>
<p align="center">Minutes Review</p>	<p>Discussion: Minutes were reviewed from the January 202 meeting.</p> <p>Decision: The Board voted to accept these approved minutes with no revisions.</p>
<p align="center">Pharmacy Program and Budget Update</p>	<p>Elizabeth Short, Joshua Moore and Angela Wilson presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - July 2021 – March 2022 Eligibles by Group - July 2021 – March 2022 Expenditures by Enrollment Group - July 2021 – March 2022 Expenditures by Service - FY22 Pharmacy Spend vs July 2021 – March 2022 Total Medicaid Spend - July 2021 – April 2022 Pharmacy Expenditures - Pharmacy Program Top 4 Drug Classes per FY - Hep C FY 2018 – FYTD 2022 - Mavyret Expenditures July 2019 – April 2022 - Forthcoming Hep C Public Facing Dashboard - Synagis Expenditures FY2019 – FYTD2022 - FY2019 – FYTD2022 Rare Disease Expenditures Per Day - Trikafta Expenditures FYTD22 - Additional discussions arose around: <ul style="list-style-type: none"> o High Risk Combination Clinical Edit changes have resulted in an expected increase in naloxone utilization o Safe at Home initiative has also resulted in an expected increase in the DipsoseRx Packets <ul style="list-style-type: none"> ▪ Suggestions arose around MHD reporting on those with initial opioids and if a subsequent DisposeRx packet was dispensed in addition ▪ Suggestions also arose around MHD collaborating with Hospice

	<ul style="list-style-type: none"> ○ New initiatives and streamlining older edits to help to decrease prior authorization, fax and call volumes to the helpdesk and overall enhanced workflow for all those involved. - Reminder provided for the July DUR meeting consisting of only clinical and fiscal edits due to the PDL vendor RFP process. PDL edit reviews are expected to resume at the October DUR meeting.
Old Business	
Old Business	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/dur/meeting.htm</p>
New Business	
New Drug Review	<p>Discussion:</p> <ul style="list-style-type: none"> - Olivia Rush reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> ○ A listing of products recommended for open access, clinical edit, preferred drug list (PDL), or continue prior authorization was emailed to the Board for discussion and action. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

Clinical and Fiscal Edit Review	
Clinical & Fiscal Edits With No Annual Changes	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Imcivree Clinical Edit o Megestrol Clinical Edit o Nulibry Clinical Edit o Oxervate Clinical Edit o Oxlumo Clinical Edit o Spravato Clinical Edit o Zokinvy Clinical Edit o Zulresso Clinical Edit - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Rick Andrews with Rhythm on Imcivree <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
Acne or Rosacea, Select Topical Agents Step Therapy Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
C5 Complement Inhibitors Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p>Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Fabry Disease Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Givlaari Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Isturisa Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Scenesse Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p>Sickle Cell Disease Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Santreis Booze with Global Blood Therapeutics on Oxbraya <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Systemic Antifungals Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Tavneos Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Voxzogo Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

Preferred Drug List Edit Review

Preferred Drug Edits With No Annual Changes

Discussion:

- Joshua Moore introduced the edits for discussion to the Board which included:
 - o Actinic Keratosis Agents, Topical
 - o Androgenic Agents
 - o Antibiotics, Inhaled
 - o Antifungals, Oral
 - o Antifungals, Topical
 - o Antihistamines & Antihistamines/Decongestant Combinations, 2nd Generation
 - o Antihistamines, Intranasal
 - o Antivirals, Herpes Oral
 - o Antivirals, Topical
 - o Benzoyl Peroxide/Antibiotic Combinations
 - o Corticosteroids, Oral Inhaled
 - o Corticosteroids, Topical
 - o Corticosteroids and Rhinitis Agents, Intranasal
 - o Cough/Cold Preparations
 - o Epinephrine Agents, Self-Injectable
 - o Fluoroquinolones, Ophthalmic
 - o Fluoroquinolones, Otic
 - o Glaucoma Agents
 - o Mast Cell Stabilizers, Ophthalmic
 - o NSAIDs, Ophthalmic
 - o Psoriasis Agents, Oral
 - o Psoriasis Agents, Topical
 - o Retinoids, Topical
 - o Ulcerative Colitis Agents, Oral
 - o Ulcerative Colitis Agents, Rectal
- No other discussion.
- No public comment provided.

Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.

<p style="text-align: center;">Asthma Policy Updates</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore and Lori Bushner reviewed the recommended updates to MHD’s Asthma Policy. - See Beta Adrenergic Agents, Nebulized; Beta Adrenergic Agents, Short Acting; and Leukotriene Receptor Modifiers PDL edits for decisions on the recommendations.
<p style="text-align: center;">Beta Adrenergic Agents, Nebulized</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p style="text-align: center;">Beta Adrenergic Agents, Short Acting</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p style="text-align: center;">Leukotriene Receptor Modifiers</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p style="text-align: center;">Anticholinergics, LABAs/ICS Combinations and PDE4 Inhibitors</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p style="text-align: center;">Anticholinergics, Long Acting Inhaled</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p style="text-align: center;">Anticholinergics, Short Acting and Combinations Inhaled</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p style="text-align: center;">Anticholinergics, LABA Combinations</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p style="text-align: center;">Antihistamines, Ophthalmic</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p style="text-align: center;">Antiparasitics, Topical</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p align="center">Atopic Dermatitis Agents, Immunomodulators</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Jim Baumann with Pfizer on Eucrisa yielded time back <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Beta Adrenergic Agents, Long Acting</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Corticosteroids, Ophthalmic Soft</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Karli Sekab with Kala Pharmaceuticals on Eysuvis o Kerry Young with Eye Center of Missouri on Eysuvis <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Hepatitis C Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p align="center">Pancreatic Enzymes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Respiratory Monoclonal Antibodies</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Katherine Rivera – Spoljaric with WashU & St. Louis Children’s Hospital on Dupixent <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Preferred Drug List Announcement</p>	<p>A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and April 2022 meeting was included in the meeting packet.</p> <p>This handout was also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/dur/meeting.htm</p>
<p align="center">Program Utilization Information – Conduent Update</p>	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Top 25 Drugs by Paid Amount 2nd Quarter 2022 (October, November, December) - Top 25 Drugs by Paid Number 2nd Quarter 2022 (October, November, December) - Call Center User Statistics February 2022 - CyberAccess Logging Information - New Drug Statistics February 2022

<p style="text-align: center;">RetroDUR Update</p>	<p>Joshua Moore introduce Ashleigh Holeman, the RetroDUR Coordinator with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Reviewed potential retro DUR interventions: <ul style="list-style-type: none"> o Concurrent Use of Opioids and Benzodiazepines <ul style="list-style-type: none"> ▪ Safe and Effective Management of Patient Receiving Opioids and Benzodiazepines Concurrently provider letter o Project Hep Cure <ul style="list-style-type: none"> ▪ Hepatitis C provider letter <ul style="list-style-type: none"> • Recommendations from the Board included sending the letter to the Medical Director of the clinic and replacing the stereotyping information with educational resources and opportunities. o Overutilization of Albuterol o Concurrent Use of Opioids and Stimulants <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p style="text-align: center;">Motion to Close</p>	<p>Rick Kegler motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.</p>

NEXT MEETING: Thursday, July 20, 2022
Missouri Coalition for Community Behavioral Healthcare
221 Metro Drive, Jefferson City, MO 65109 and WebEx

Roll Call for April 20, 2022				
	<u>Action Item</u>			
<u>Board Member</u>	January Meeting Minutes	All Recommendations: Block Vote for CE, FE and PDL Edits	Closing	Adjournment
Susan Abdel-Rahman	Y	Y	Y	Y
Charlene Heyde	Y	Y	Y	Y
Sandra Bollinger	AB	MY	Y	Y
Julie Ferguson	AB	Y	Y	Y
Lisa Pierce	MY	SY	Y	MY
Jennifer Passanise	Y	Y	Y	Y
Stacy Mangum	SY	Y	SY	Y
Ginger Nicol	Y	Y	Y	Y
Rick Kegler	Y	Y; AB from Voxzogo CE	MY	Y
Kim Eisenstein	Y	Y	Y	SY

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain